Radiopharm Theranostics Reported FY25 Cash Balance Of $29.12M, Operating Cash Flow Of $36.67M, Confirmed Guidance of Cash Runway Through To Mid-2026
Benzinga
Jul 29
Financial update
The following is a summary of the Appendix 4C Cash Flow Report:
The year-end closing cash balance was $29.12 million, a rise from $18.58 million at the close of the previous year.
Net cash outflows from operating activities for the year totaled $36.67 million. Direct Research and Development expenditure and Staff Costs comprised over 90% of the total operating expenditure for the year and quarter.
On July 16, 2025, the Company reported the receipt of $4.58 million for the research and development tax incentive and associated interest for the 2024 financial year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.